SSA
TERN

Schonfeld Strategic Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.74M Sell
165,725
-588,512
-78% -$24.2M 0.06% 332
2025
Q4 		$30.5M Sell
754,237
-1,137,688
-60% -$26.3M 0.14% 122
2025
Q3 		$14.2M Sell
1,891,925
-1,157,966
-38% -$7.39M 0.08% 266
2025
Q2 		$11.4M Sell
3,049,891
-794,976
-21% -$2.48M 0.08% 299
2025
Q1 		$10.6M Sell
3,844,867
-906,639
-19% -$3.7M 0.06% 300
2024
Q4 		$26.3M Buy
4,751,506
+1,461,680
+44% +$9.9M 0.15% 114
2024
Q3 		$27.4M Buy
3,289,826
+1,021,398
+45% +$8.4M 0.18% 81
2024
Q2 		$15.4M Buy
2,268,428
+1,072,634
+90% +$6.5M 0.1% 233
2024
Q1 		$7.84M Buy
1,195,794
+787,936
+193% +$5.15M 0.05% 466
2023
Q4 		$2.65M Buy
407,858
+316,450
+346% +$1.67M 0.02% 707
2023
Q3 		$460K Sell
91,408
-27,528
-23% -$175K ﹤0.01% 1226
2023
Q2 		$1.04M Buy
118,936
+3,684
+3% +$42.9K 0.01% 957
2023
Q1 		$1.36M Buy
+115,252
New +$1.1M 0.01% 822

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Schonfeld Strategic Advisors's TERN Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Terns Pharmaceuticals (TERN) stake by 78% in Q1 2026, selling an estimated $24.2M and leaving 165,725 shares worth $8.74M. The position accounts for 0.06% of the portfolio, ranked #332.

Schonfeld Strategic Advisors first reported a position in TERN in Q1 2023 and has held it in 13 quarters since. The position peaked at $30.5M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Schonfeld Strategic Advisors held 165,725 shares of Terns Pharmaceuticals worth $8.74M as of Q1 2026.
  • Schonfeld Strategic Advisors sold 588,512 Terns Pharmaceuticals shares in Q1 2026, an estimated $24.2M.
  • Terns Pharmaceuticals made up 0.06% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #332 holding.
  • Schonfeld Strategic Advisors first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Schonfeld Strategic Advisors's Terns Pharmaceuticals position peaked at $30.5M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.